Huahai pharmaceutical's production approval of class 3.1 new anti gout drug, non Brest, has been accepted
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on June 4 on the website of the State Food and Drug Administration (CFDA), the approval documents for the production of non brescial APIs and tablets for class 3.1 chemical drugs declared by Huahai pharmaceutical were accepted Febuxta is a new anti gout drug, which was successfully developed by Japanese Imperial pharmaceutical In 2008 and 2009, it was approved by the European Union and FDA In 2010, the annual sales of the product reached 1.2 billion US dollars According to CFDA, there are currently three domestic enterprises approved to produce the drug preparation last year They are: Hangzhou zhuyangxin Pharmaceutical Co., Ltd., a subsidiary of Huadong Pharmaceutical Group, Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd., a holding subsidiary of Fosun Pharmaceutical (600196 SH), and Hengrui Pharmaceutical (600276 SH) In addition to Huahai Pharmaceutical Co., Ltd., there are four other enterprises, i.e Sinopharm group and Zhuhai Federation, which are also applying for production.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
